PURPOSE: The primary objective of this study was to determine the rate of pathological response after preoperative celecoxib and concurrent taxane-based chemotherapy in patients with cancer of the esophagus and gastroesophageal junction. METHODS: Thirty-nine patients were enrolled in this single-arm, phase II clinical trial. Patients were administered daily celecoxib in combination with two to three cycles of carboplatin and paclitaxel with preoperative intent. Levels of cyclooxygenase (COX)-2 expression in resected tumors were analyzed by immunohistochemistry and correlated with clinical outcome measures. Postoperatively, patients were administered daily celecoxib for 1 year or until documented tumor recurrence. RESULTS: All patients received two to three cycles of chemotherapy plus celecoxib 800 mg/d. Toxicities were as expected. A major clinical response (complete response + partial response) was noted in 22 patients (56%); six patients (15%) had a complete clinical response. Thirty-seven patients underwent esophagectomy. Five patients had a major pathological response (12.8%). Four-year overall and disease-free survivals were 40.9% and 30.3%, respectively. Patients with tumors expressing COX-2 demonstrated a higher likelihood of a major clinical response response (62% versus 50%) and an improved overall survival, compared with patients with COX-2-negative tumors. CONCLUSIONS: Preoperative celecoxib with concurrent chemotherapy demonstrated sufficient effect on pathologic response to warrant further study. Patients with tumors expressing COX-2 demonstrated trends toward improved response to preoperative therapy and improved overall survival compared with nonexpressors.
PURPOSE: The primary objective of this study was to determine the rate of pathological response after preoperative celecoxib and concurrent taxane-based chemotherapy in patients with cancer of the esophagus and gastroesophageal junction. METHODS: Thirty-nine patients were enrolled in this single-arm, phase II clinical trial. Patients were administered daily celecoxib in combination with two to three cycles of carboplatin and paclitaxel with preoperative intent. Levels of cyclooxygenase (COX)-2 expression in resected tumors were analyzed by immunohistochemistry and correlated with clinical outcome measures. Postoperatively, patients were administered daily celecoxib for 1 year or until documented tumor recurrence. RESULTS: All patients received two to three cycles of chemotherapy plus celecoxib 800 mg/d. Toxicities were as expected. A major clinical response (complete response + partial response) was noted in 22 patients (56%); six patients (15%) had a complete clinical response. Thirty-seven patients underwent esophagectomy. Five patients had a major pathological response (12.8%). Four-year overall and disease-free survivals were 40.9% and 30.3%, respectively. Patients with tumors expressing COX-2 demonstrated a higher likelihood of a major clinical response response (62% versus 50%) and an improved overall survival, compared with patients with COX-2-negative tumors. CONCLUSIONS: Preoperative celecoxib with concurrent chemotherapy demonstrated sufficient effect on pathologic response to warrant further study. Patients with tumors expressing COX-2 demonstrated trends toward improved response to preoperative therapy and improved overall survival compared with nonexpressors.
Authors: Huan Xi; Stephan E Baldus; Ute Warnecke-Eberz; Jan Brabender; Susanne Neiss; Ralf Metzger; Frederike C Ling; Hans P Dienes; Elfriede Bollschweiler; Stefan Moenig; Rolf P Mueller; Arnulf H Hoelscher; Paul M Schneider Journal: Clin Cancer Res Date: 2005-12-01 Impact factor: 12.531
Authors: Jurriaan B Tuynman; Christianne J Buskens; Kristel Kemper; Fiebo J W ten Kate; G Johan A Offerhaus; Dirk J Richel; J Jan B van Lanschot Journal: Ann Surg Date: 2005-12 Impact factor: 12.969
Authors: Scott D Solomon; John J V McMurray; Marc A Pfeffer; Janet Wittes; Robert Fowler; Peter Finn; William F Anderson; Ann Zauber; Ernest Hawk; Monica Bertagnolli Journal: N Engl J Med Date: 2005-02-15 Impact factor: 91.245
Authors: D P Kelsen; B Minsky; M Smith; J Beitler; D Niedzwiecki; D Chapman; M Bains; M Burt; R Heelan; B Hilaris Journal: J Clin Oncol Date: 1990-08 Impact factor: 44.544
Authors: Robert Mutter; Bo Lu; David P Carbone; Ildiko Csiki; Luigi Moretti; David H Johnson; Jason D Morrow; Alan B Sandler; Yu Shyr; Fei Ye; Hak Choy Journal: Clin Cancer Res Date: 2009-03-10 Impact factor: 12.531
Authors: H Takatori; S Natsugoe; H Okumura; M Matsumoto; Y Uchikado; T Setoyama; K Sasaki; K Tamotsu; T Owaki; S Ishigami; T Aikou Journal: Eur J Surg Oncol Date: 2007-06-05 Impact factor: 4.424
Authors: Corinne M Doll; Kathryn Winter; David K Gaffney; Janice K Ryu; Anuja Jhingran; Adam P Dicker; Joanne B Weidhaas; Brigitte E Miller; Anthony M Magliocco Journal: Int J Gynecol Cancer Date: 2013-01 Impact factor: 3.437
Authors: James M Cleary; Harvey J Mamon; Jackie Szymonifka; Raphael Bueno; Noah Choi; Dean M Donahue; Panos M Fidias; Henning A Gaissert; Michael T Jaklitsch; Matthew H Kulke; Thomas P Lynch; Steven J Mentzer; Jeffrey A Meyerhardt; Richard S Swanson; John Wain; Charles S Fuchs; Peter C Enzinger Journal: BMC Cancer Date: 2016-07-13 Impact factor: 4.430
Authors: Pilar Jiménez; Eduardo Chueca; María Arruebo; Mark Strunk; Estela Solanas; Trinidad Serrano; María A García-González; Ángel Lanas Journal: Front Pharmacol Date: 2017-05-30 Impact factor: 5.810